Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 106
- Registration Number
- NCT03664440
- Locations
- 🇹🇭
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT03227653
- Locations
- 🇹🇿
Mawenzi Regional Hospital, Moshi, Kilimanjaro Region, Tanzania
🇹🇿Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro Region, Tanzania
🇹🇿Kiboroloni Dispensary, Moshi, Tanzania
Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2022-07-20
- Target Recruit Count
- 495
- Registration Number
- NCT03088410
- Locations
- 🇧🇼
Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
Antiretroviral Regime for Viral Eradication in Newborns
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 600
- Registration Number
- NCT02712801
- Locations
- 🇨🇳
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 73
- Registration Number
- NCT02431975
- Locations
- 🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa
Early Infant HIV Treatment in Botswana
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Harvard School of Public Health (HSPH)
- Target Recruit Count
- 67
- Registration Number
- NCT02369406
- Locations
- 🇧🇼
Botswana Harvard HIV/AIDS Institute Partnership, Gaborone, Botswana
A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Adeniyi Olagunju
- Target Recruit Count
- 460
- Registration Number
- NCT02269462
- Locations
- 🇳🇬
St Monica's Hospital, Adikpo, Benue State, Nigeria
🇳🇬Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria
🇳🇬St Mary's Hospital, Okpoga, Benue State, Nigeria
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Ratiopharm GmbH
- Target Recruit Count
- 46
- Registration Number
- NCT02202005
- Locations
- 🇬🇧
Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02184091
Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5
- Registration Number
- NCT02184286
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.